Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Clinical Oncology

• Publication date

  2014-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2014.55.2984PMID 25349301
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.

  2013cited by this paper
• Abstract PD09-03: Impact of BRCA1/2 Mutation Status in TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer.

  2012cited by this paper
• Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

  2011cited by this paper
• Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

  2011cited by this paper
• Molecular stratification of triple-negative breast cancers.

  2011cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• Abstract A226: Mechanism of action of iniparib: Stimulation of reactive oxygen species (ROS) production in an iniparib-sensitive breast cancer cell line.

  2011cited by this paper
• Management of triple negative breast cancer.

  2010cited by this paper
• Molecular stratification of triple-negative breast cancers.

  2010cited by this paper
• Directed therapy of subtypes of triple-negative breast cancer.

  2010cited by this paper
• Directed therapy of subtypes of triple-negative breast cancer.

  2010cited by this paper
• Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.

  2010cited by this paper
• Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients.

  2010cited by this paper
• Triple-negative breast cancer: a clinical update

  2010cited by this paper
• Triple-negative breast cancer.

  2010cited by this paper
• Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.

  2009cited by this paper
• Pattern of metastatic spread in triple-negative breast cancer

  2009cited by this paper
• Abstract #5552: BSI-201 enhances the activity of multiple classes of cytotoxic agents and irradiation in triple negative breast cancer

  2009cited by this paper
• Breast cancer as a global health concern.

  2009cited by this paper
• Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.

  2009cited by this paper
• A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer.

  2008cited by this paper
• Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.

  2008cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

  2007cited by this paper
• The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

  2007cited by this paper
• Triple-negative metastatic/recurrent breast cancer: Treatment with paclitaxel/carboplatin combination chemotherapy

  2007cited by this paper

• High-throughput screening of drug libraries identifies a new synergistic drug combination for the treatment of retinoblastoma.

  2026cites this paper
• PTPN2 inhibits TG-induced ERS-initiated TNBC apoptosis through the mitochondrial pathway

  2025cites this paper
• Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy for BRCA1-Associated Triple-Negative Breast Cancer

  2025cites this paper
• Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with chemotherapy in locally advanced or metastatic triple-negative breast cancer: the ImmunoBreast phase Ib clinical trial

  2025cites this paper
• Novel clinical potential of poly (ADP‑ribose) polymerase inhibitors in triple‑negative breast cancer: Mechanistic insights and clinical applications (Review)

  2025cites this paper
• Application and Progress of Antibody-Drug Conjugates (ADCs) in the Treatment of Metastatic Triple-Negative Breast Cancer

  2025cites this paper
• Poly (ADP-ribose) polymerase inhibitors in cancer therapy

  2025cites this paper
• Restricted mean survival time based on Wu-Kolassa estimator compared to Kaplan-Meier estimator.

  2025cites this paper
• A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer

  2025cites this paper
• PARP inhibitor-based combination therapies: enriching synergistic forces against BRCA-mutated metastatic breast cancer

  2025cites this paper
• Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Combination with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis

  2025cites this paper
• Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence

  2025cites this paper
• Comprehensive review of drug-mediated ICD inhibition of breast cancer: mechanism, status, and prospects

  2024cites this paper
• Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer

  2024cites this paper
• Reawakening the Master Switches in Triple-Negative Breast Cancer: A Strategic Blueprint for Confronting Metastasis and Chemoresistance via MicroRNA-200/205: a systematic review.

  2024cites this paper
• First-line carboplatin-based chemotherapy may be beneficial for HER2-low advanced breast cancer: A retrospective analysis

  2024cites this paper
• DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

  2024cites this paper
• Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer

  2024cites this paper
• High-throughput drug screening using a library of antibiotics targeting cancer cell lines that are resistant and sensitive to gemcitabine.

  2024cites this paper
• Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiency

  2024cites this paper
• Targeted Treatment of Metastatic Triple-Negative Breast Cancer: A Systematic Review

  2024cites this paper
• Efficacy and safety of PARPis combined with an ICIs for advanced or metastatic triple-negative breast cancer: a single-arm meta-analysis

  2024cites this paper
• Molecularly Targeted Therapies In Breast Cancer: A Traditional Review

  2024cites this paper
• Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data

  2024cites this paper
• Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer

  2023cites this paper
• Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type

  2023cites this paper
• Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355

  2023cites this paper
• Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis

  2023cites this paper
• DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: a meta-analysis and systematic review

  2023cites this paper
• PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials

  2023cites this paper
• Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study

  2023cites this paper
• Evolution of the Development of PARP Inhibitors.

  2023cites this paper
• Effects of different targeted therapies associated with adjuvant chemotherapy on clinical remission, survival and safety in patients with triple-negative breast cancer: a systematic review and meta-analysis.

  2023cites this paper
• Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation.

  2023cites this paper
• Extracellular Vesicles in Triple–Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential

  2023cites this paper
• Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study

  2023cites this paper
• Poly(ADP-ribose) polymerase inhibitors in the treatment landscape of triple-negative breast cancer (TNBC)

  2023cites this paper
• Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast Cancer.

  2023cites this paper
• The Routledge Companion to Philosophy of Medicine

  2023cites this paper
• Differential effects of poly(ADP ribose) polymerase inhibitor-based metronomic therapy on programmed death-ligand 1 and matrix-associated factors in human myeloid cells.

  2022cites this paper
• Clinical remission in paired phase two and three studies in inflammatory bowel disease: a systematic review with meta-analysis

  2022cites this paper
• CD4+ T cells drive an inflammatory, TNF-α/IFN-rich tumor microenvironment responsive to chemotherapy.

  2022cites this paper
• Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.

  2022cites this paper
• The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair

  2022cites this paper
• ‘Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research’

  2022cites this paper
• Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases

  2022influential citation
• Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison.

  2022cites this paper
• Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial.

  2022cites this paper
• Kết quả sống thêm ở bệnh nhân ung thu vú bộ ba âm tính tái phát di căn hóa trị phác đồ Gemcitabine-Carboplatin

  2022cites this paper
• Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers

  2022cites this paper
• A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer

  2022cites this paper
• PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers

  2022cites this paper
• CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy.

  2022cites this paper
• PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer

  2022cites this paper
• Potential molecular mechanisms and clinical progress in liver metastasis of breast cancer.

  2022cites this paper
• High expression of cuproptosis-related SLC31A1 gene in relation to unfavorable outcome and deregulated immune cell infiltration in breast cancer: an analysis based on public databases

  2022cites this paper
• Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials.

  2021cites this paper
• Role of Platinums in Triple-Negative Breast Cancer

  2021cites this paper
• Breast cancer liver metastasis: current and future treatment approaches

  2021cites this paper
• An Amphiphilic PEGylated Peptide Dendron-Gemcitabine Prodrug-Based Nanoagent for Cancer Therapy.

  2021cites this paper
• Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities

  2021cites this paper
• Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy

  2021influential citation
• Extraction of chlorophyll and carotenoids loaded into chitosan as potential targeted therapy and bio imaging agents for breast carcinoma.

  2021cites this paper
• Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer

  2021cites this paper
• For evidence-based clinical long-term follow-up of childhood cancer survivors , risk strati � cation is required

  2021cites this paper
• Real-World Outcome of Platinum-Based Chemotherapy in Advanced Breast Cancer (ABC): A Retrospective Study from a Tertiary Cancer Center in India

  2021cites this paper
• Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis

  2021cites this paper
• Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment.

  2021cites this paper
• Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance

  2021cites this paper
• Exploring New Targets and Publication Tendency of Triple Negative Breast Cancer: A 20-Year Bibliometric Analysis

  2021cites this paper
• A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

  2021cites this paper
• Lipoma HMGIC fusion partner expression differs in primary tumors and lymph node metastases in malignancy.

  2021cites this paper
• In diffuse intrinsic pontine gliomas, non-coding RNA expression is significantly varied dependent on overall survival

  2021cites this paper
• ZFX expression is connected with improved survival in patients with breast cancer

  2021cites this paper
• Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis

  2021cites this paper
• mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer

  2021cites this paper
• O-nitrobenzyl liposomes with dual-responsive release capabilities for drug delivery

  2021cites this paper
• Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer

  2021cites this paper
• A narrative review of chemotherapy in advanced triple negative breast cancer

  2021cites this paper
• E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group

  2021cites this paper
• PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.

  2021influential citation
• Immunotherapy as maintenance treatment in metastatic triple negative breast cancer

  2021cites this paper
• Integrating PARP inhibitors into the management of breast cancer: where are we?

  2020cites this paper
• Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

  2020cites this paper
• Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy

  2020cites this paper
• Nanoliposomes as Multidrug Carrier of Gemcitabine/Paclitaxel for the Effective Treatment of Metastatic Breast Cancer Disease: A Comparison with Gemzar and Taxol

  2020cites this paper
• HRWR: Predicting Potential Efficacious Drug Combination Based on Hypergraph Random Walk with Restart

  2020cites this paper
• Network meta-analysis of targeted drugs in combination with chemotherapy for advanced/metastatic triple-negative breast cancer treatment

  2020cites this paper
• Triple-negative breast cancer therapy: Current and future perspectives (Review)

  2020cites this paper
• Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

  2020cites this paper
• Why natural killer cells in triple negative breast cancer?

  2020cites this paper
• Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.

  2020cites this paper
• The evolving management of metastatic triple negative breast cancer.

  2020cites this paper
• Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity

  2020cites this paper
• Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer

  2020cites this paper
• Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020cites this paper
• Targeting homologous recombination (HR) repair mechanism for cancer treatment: discovery of new potential UCHL-3 inhibitors via virtual screening, molecular dynamics and binding mode analysis

  2020cites this paper
• Treatment options for Indonesian triple negative breast cancer patients: a literature review of current state and potentials for future improvement

  2020cites this paper
• Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions

  2020cites this paper
• Long Non-Coding RNA (lncRNA) BMP/OP-Responsive Gene (BORG) Promotes Development of Chemoresistance of Colorectal Cancer Cells to Carboplatin

  2020cites this paper